grepcent public filings, reorganized for comparison

DOXEPIN HYDROCHLORIDE — FDA application ANDA207482

Application ANDA207482 · type ANDA · FDA status: approved · original approval 2017-06-28

Listed sponsor: AMNEAL PHARMS CO · AMRX company profile · exact_unique

Sponsor as listed in Drugs@FDA at retrieval (2026-08-07); FDA sponsor listings can lag ownership transfers.

FDA application facts

ProductFDA-listed trade nameActive ingredientDosage formRouteStrengthMarketing statusTE codeRLD
001DOXEPIN HYDROCHLORIDEDOXEPIN HYDROCHLORIDECAPSULEORALEQ 10MG BASEPrescriptionABNo
002DOXEPIN HYDROCHLORIDEDOXEPIN HYDROCHLORIDECAPSULEORALEQ 25MG BASEPrescriptionABNo
003DOXEPIN HYDROCHLORIDEDOXEPIN HYDROCHLORIDECAPSULEORALEQ 50MG BASEPrescriptionABNo
004DOXEPIN HYDROCHLORIDEDOXEPIN HYDROCHLORIDECAPSULEORALEQ 75MG BASEPrescriptionABNo
005DOXEPIN HYDROCHLORIDEDOXEPIN HYDROCHLORIDECAPSULEORALEQ 100MG BASEPrescriptionABNo

Product, form, strength, reference-drug and marketing-status fields: Drugs@FDA data files; TE and RLD fields: Orange Book data files. Retrieved 2026-08-07.

Orange Book patent and exclusivity listings

No Orange Book patent or exclusivity listings joined to this application.

Compound cross-links

Ingredient–compound links use FDA openFDA/GSRS identifiers and an exact lmmol InChIKey join. Ingredient names cannot create a link.

Related pages

Sponsor company · FDA-approved application index

Peer clusters: No published peer-cluster link for this sponsor.

Sources: Drugs@FDA · Orange Book · openFDA application record. FDA data retrieved 2026-08-07.

Regulatory listing data as published by FDA; not medical or investment advice.